Zespól żyly glównej górnej u chorych na raka pluca – rola radioterapii

Abstract

Author(s): Elżbieta Plula, Pawel Blecharz, Marian Reinfuss, Tomasz Walasek, Magdalena Pęcak, Marta Rogowska

Evaluation of efficacy, complications and prognostic factors in patients with lung cancer, suffering from superior vena cava syndrome (SVCS) is presented in the paper. Literature analysis shows that complete or partial remission of the symptoms is observed in 70-95% of patients. In 50-70% of patients the remission is observed in the first 2 weeks of irradiation. Complication rates is acceptable - in 26-50% of patients authors observe mild or moderate oesophagitis, 8-10% of patients suffer from transient nausea and vomiting. Literature review shows median overall survival rate oscillating from 12 to 40 weeks, twelve-month survival rate - from 20 to 25% and 5-year survival rate - from 2 to 5%. The only recognized prognostic factor for symptoms remission in lung cancer patients with SVCS is histological type of cancer. Complete remission of SVCS is observed in 78% of patients with small cell lung cancer, however only in 63% of patients with non-small cell lung cancer.

Share this article